... as well as the launch of the pioneering 100,000 Genomes project - the first project of its kind in the world.
But what is next for the UK when it comes to genomics? The answer was provided in the recently published Genome UK paper, which sets out the future of the UK in the field of genomics, particularly how different bodies in the genomic sector will come together to utilise their research and resources in this field to progress and prioritise genomic science for the benefit of patients.
The report does not skimp on detail and at 64 pages long seeks to provide some much longed-for answers to where the genomics landscape is heading and who will be leading the charge both on behalf of the government institutions behind the move, as well as the commercial and public bodies responsible for taking the technology from scientific theory to patient therapies.
The Executive Summary in the report summarises the paper and the vision of Genome UK as follows:
The goals above are to be achieved through five areas:
The UK has been at the forefront of the genomics field for a number of years. Despite the current uncertainty due to COVID-19 and the final stages of the Brexit transition period, this report gives hope that the UK will continue to lead the world in this area. Ultimately, this would benefit patients and their families. As a legal advisor to some amazing organisations in this space, I am excited to see what the future holds and be a part of this journey.
For us here at VWV, the release of the Genome UK report is particularly exciting as it further supports our view that Britain has a great future in this area, a view that we are sharing with the sector at our annual PING Conference this year under the theme 'Britain's Great Life Sciences Future - Genomics, Personalised Medicine and AI'.
At the virtual PING Conference, we have a high quality of speakers on the hot topics where Britain is playing such a big part in shaping the future for the next stage of pharma - focusing on how things are dramatically changing in Genomics, Personalised Medicine and through the use of AI to do things such as change the supply chain and increase the ability to provide new treatments including in areas of unmet need.
We currently have 150 people booked to attend and there will be some great networking opportunities to mix with big pharma, mid-size pharma, established smaller pharma companies, start-ups, HE and numerous other sector specialists, specialist industry consultants, and sector press.